+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cellmid Ltd (CDY) - Product Pipeline Analysis, 2018 Update

  • ID: 4658268
  • Company Profile
  • October 2018
  • 37 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Holista CollTech Ltd
  • Immutep Ltd
  • Viralytics Ltd
  • MORE
Summary

Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair loss products and evolis products. Cellmid develops CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. The company markets its products in Australia and Japan. Cellmid is headquartered in Sydney, New South Wales, Australia.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Cellmid Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Holista CollTech Ltd
  • Immutep Ltd
  • Viralytics Ltd
  • MORE
Cellmid Ltd Company Overview
Cellmid Ltd Company Snapshot
Cellmid Ltd Pipeline Products and Ongoing Clinical Trials Overview
Cellmid Ltd – Pipeline Analysis Overview
Cellmid Ltd - Key Facts
Cellmid Ltd - Major Products and Services
Cellmid Ltd Pipeline Products by Development Stage
Cellmid Ltd Pipeline Products Overview
CK3000 Cancer Screening Test
CK3000 Cancer Screening Test Product Overview
Companion Diagnostic Assay - Glioblastoma
Companion Diagnostic Assay - Glioblastoma Product Overview
CS5000 Cancer Screening Test
CS5000 Cancer Screening Test Product Overview
MK Protein - Cancer
MK Protein - Cancer Product Overview
MK-ELISA Assay - Bile Duct Cancer
MK-ELISA Assay - Bile Duct Cancer Product Overview
MK-ELISA Assay - Colorectal Cancer
MK-ELISA Assay - Colorectal Cancer Product Overview
MK-ELISA Assay - Esophageal Cancer
MK-ELISA Assay - Esophageal Cancer Product Overview
MK-ELISA Assay - Gastrointestinal Cancer
MK-ELISA Assay - Gastrointestinal Cancer Product Overview
MK-ELISA Assay - Metastatic Colorectal Cancer
MK-ELISA Assay - Metastatic Colorectal Cancer Product Overview
MK-ELISA Assay - Prostate Cancer
MK-ELISA Assay - Prostate Cancer Product Overview
MK-ELISA Assay - Stromal Cancer
MK-ELISA Assay - Stromal Cancer Product Overview
MK-ELISA Assay - Thyroid Cancer
MK-ELISA Assay - Thyroid Cancer Product Overview
Cellmid Ltd - Key Competitors
Cellmid Ltd - Key Employees
Cellmid Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cellmid Ltd, Recent Developments
May 30, 2018: 5th Midkine Symposium Reinforces Clinical Potential For Cellmid’S Biotechnology Assets
May 29, 2018: Cellmid announces Change of Address
Jan 09, 2018: Cellmid Quarterly Operational Update
Oct 25, 2017: Cellmid: Notes to the Appendix 4C
Oct 16, 2017: Cellmid Appoints Dr Martin Cross as Non-executive Director
Sep 27, 2017: Cellmid's FY2017 Results Presentation
May 26, 2016: Cellmid provides update on Japanese sale
May 09, 2016: Significant Scientific Appointment for Cellmid Advisory Board Chair
Apr 08, 2016: Cellmid: Midkine Strategy Update
Feb 25, 2016: Interim Financial Report For the Half-Year Ended 31 December 2015 : Cellmid
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Cellmid Ltd Pipeline Products and Ongoing Clinical Trials Overview
Cellmid Ltd Pipeline Products by Equipment Type
Cellmid Ltd Pipeline Products by Indication
Cellmid Ltd, Key Facts
Cellmid Ltd, Major Products and Services
Cellmid Ltd Number of Pipeline Products by Development Stage
Cellmid Ltd Pipeline Products Summary by Development Stage
CK3000 Cancer Screening Test - Product Status
CK3000 Cancer Screening Test - Product Description
Companion Diagnostic Assay - Glioblastoma - Product Status
Companion Diagnostic Assay - Glioblastoma - Product Description
CS5000 Cancer Screening Test - Product Status
CS5000 Cancer Screening Test - Product Description
MK Protein - Cancer - Product Status
MK Protein - Cancer - Product Description
MK-ELISA Assay - Bile Duct Cancer - Product Status
MK-ELISA Assay - Bile Duct Cancer - Product Description
MK-ELISA Assay - Colorectal Cancer - Product Status
MK-ELISA Assay - Colorectal Cancer - Product Description
MK-ELISA Assay - Esophageal Cancer - Product Status
MK-ELISA Assay - Esophageal Cancer - Product Description
MK-ELISA Assay - Gastrointestinal Cancer - Product Status
MK-ELISA Assay - Gastrointestinal Cancer - Product Description
MK-ELISA Assay - Metastatic Colorectal Cancer - Product Status
MK-ELISA Assay - Metastatic Colorectal Cancer - Product Description
MK-ELISA Assay - Prostate Cancer - Product Status
MK-ELISA Assay - Prostate Cancer - Product Description
MK-ELISA Assay - Stromal Cancer - Product Status
MK-ELISA Assay - Stromal Cancer - Product Description
MK-ELISA Assay - Thyroid Cancer - Product Status
MK-ELISA Assay - Thyroid Cancer - Product Description
Cellmid Ltd, Key Employees
Cellmid Ltd, Subsidiaries
Glossary

List of Figures
Cellmid Ltd Pipeline Products by Equipment Type
Cellmid Ltd Pipeline Products by Development Stage
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Holista CollTech Ltd
  • Immutep Ltd
  • Viralytics Ltd
Note: Product cover images may vary from those shown
Adroll
adroll